Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0402 | 0.2066 | 1 |
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0296 | 0.1163 | 0.8166 |
Loa Loa (eye worm) | hypothetical protein | 0.0402 | 0.2066 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0371 | 0.1805 | 1 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0402 | 0.2066 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0173 | 0.012 | 0.5 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0327 | 0.1424 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1335 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0173 | 0.012 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.1335 | 1 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0274 | 0.0973 | 0.5392 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.1335 | 1 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.1335 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0173 | 0.012 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.1335 | 1 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0173 | 0.012 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0173 | 0.012 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.1335 | 1 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1335 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.